Comparing the economic and health benefits of different approaches to diagnosing Clostridium difficile infection Sarah M. Bartsch, Craig A. Umscheid,

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Rectal bacteriotherapy for recurrent Clostridium difficile-associated diarrhoea: results from a case series of 55 patients in Denmark 2000–2012 M. Tvede,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Symptomatic cytomegalovirus gastrointestinal infection with positive quantitative real- time PCR findings in apparently immunocompetent patients: a case.

J.-C. Lagier Clinical Microbiology and Infection

O.J. Dyar, G. Tebano, C. Pulcini Clinical Microbiology and Infection

D. Khalil, M. Hultin, M.U. Rashid, B. Lund

Control of multidrug-resistant Gram-negative bacteria in low- and middle-income countries—high impact interventions without much resources N. Singh,

Impact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis J.

Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis T. Steinmetz, N.

European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Data review and recommendations for diagnosing Clostridium difficile-infection.

Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications T.-L. Liao, Y.-M.

Migrant health—a cause for concern?

Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics Y.H. van Beurden, S. Nezami,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

R. Cantón Clinical Microbiology and Infection

A. F. Simonetti, C. Garcia-Vidal, D. Viasus, D. García-Somoza, J

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

E. Bouza Clinical Microbiology and Infection

Increased incidence of nitroimidazole-refractory giardiasis at the Hospital for Tropical Diseases, London: 2008–2013 L.E.B. Nabarro, R.A. Lever, M. Armstrong,

Clinical characteristics and outcome of patients with Clostridium difficile infection diagnosed by PCR versus a three-step algorithm C. Beaulieu, L.-L.

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

Vector control: a cornerstone in the malaria elimination campaign

Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non–severely ill patients

Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis J. Jung, M.Y. Kim, H.J. Lee, Y.S. Park, S.-O.

E. Bouza, P. Muñoz, R. Alonso Clinical Microbiology and Infection

Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients S. Erb, R. Frei,

F. Barbut, L. Surgers, C. Eckert, B. Visseaux, M. Cuingnet, C

Identification of patients at high risk for Clostridium difficile infection: development and validation of a risk prediction model in hospitalized patients.

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

B. Y. Lee, Z. S. Wettstein, S. M. McGlone, R. R. Bailey, C. A

Early invasive fungal infections and colonization in patients with cirrhosis admitted to the intensive care unit E. Theocharidou, B. Agarwal, G. Jeffrey,

M.H. Wilcox Clinical Microbiology and Infection

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

S. Imbert, J.-Y. Brossas, M. Palous, I. Joly, I. Meyer, A. Fekkar

The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort study E. Manea, J. Sojo-Dorado, R.E. Jipa, S.N.

Levofloxacin in the treatment of ventilator-associated pneumonia

R. Bitterman, M. Paul, D. Polak, Y. Geffen

Mathematical modeling of Clostridium difficile infection

Laboratory diagnosis of Clostridium difficile disease

European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection M.J.T.

The economic burden of Clostridium difficile

Systematic review of antibiotic consumption in acute care hospitals

Abstracts cont. Clinical Microbiology and Infection

N. Jazmati, M. Hellmich, B. Ličanin, G. Plum, A.J. Kaasch

Testing patients with non-specific symptoms for antibodies against Borrelia burgdorferi sensu lato does not provide useful clinical information about.

Current experience in treating invasive zygomycosis with posaconazole

Vaccinations against respiratory tract infections at Hajj

How well does physician selection of microbiologic tests identify Clostridium difficile and other pathogens in paediatric diarrhoea? Insights using multiplex.

R. U. Varier, E. Biltaji, K. J. Smith, M. S. Roberts, M. K. Jensen, J

S. M. Bartsch, J. A. McKinnell, L. E. Mueller, L. G. Miller, S. K

Increasing numbers of hospitalizations and deaths with mention of Clostridium difficile infection, north-eastern Italy, 2008–2013 U. Fedeli, E. Schievano,

Microbiologic factors affecting Clostridium difficile recurrence

Diarrhoea in general practice: when should a Clostridium difficile infection be considered? Results of a nested case-control study M.P.M. Hensgens, O.M.

C.P. Kelly Clinical Microbiology and Infection

The atypical pneumonias: clinical diagnosis and importance

Virology: a scientific discipline facing new challenges

Modelling during an emergency: the 2009 H1N1 influenza pandemic

First implementation of frozen, capsulized faecal microbiota transplantation for recurrent Clostridium difficile infection into clinical practice in Europe

Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci V. Sakka, S. Tsiodras, L. Galani, A. Antoniadou,

Trends and changes in Clostridium difficile diagnostic policies and their impact on the proportion of positive samples: a national survey A. Adler, Y.

J.L. Balcázar Clinical Microbiology and Infection

Typing of Clostridium difficile

Great oaks from little acorns grow—21 years of CMI

Impact of antibiotic restrictions: the patient's perspective

CMI readers' survey Clinical Microbiology and Infection

Rajko Saletinger, Mario Poljak, Franc Strle

The future of diagnostic bacteriology

Risk factors and clinical outcomes of candidaemia in patients treated for Clostridium difficile infection A. Russo, M. Falcone, M. Fantoni, R. Murri,

Presentation transcript:

Comparing the economic and health benefits of different approaches to diagnosing Clostridium difficile infection Sarah M. Bartsch, Craig A. Umscheid, Irving Nachamkin, Keith Hamilton, Bruce Y. Lee Clinical Microbiology and Infection Volume 21, Issue 1, Pages 77.e1-77.e9 (January 2015) DOI: 10.1016/j.cmi.2014.07.002 Copyright © 2014 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 1 Model flow for the various CDI diagnostic testing strategies. CDI, Clostridium difficile infection; GDH, glutamate dehydrogenase; NAAT, nucleic acid amplification test. Clinical Microbiology and Infection 2015 21, 77.e1-77.e9DOI: (10.1016/j.cmi.2014.07.002) Copyright © 2014 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 2 Number of timely CDI treatments, delayed CDI treatments, unnecessary CDI treatments and total costs per 1000 patients tested by diagnostic approach for various probabilities of CDI with a 3-day treatment delay when 80% of patients with submitted samples had clinically significant diarrhoea. CDI, Clostridium difficile infection; GDH, glutamate dehydrogenase; NAAT, nucleic acid amplification test. Clinical Microbiology and Infection 2015 21, 77.e1-77.e9DOI: (10.1016/j.cmi.2014.07.002) Copyright © 2014 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 3 Impact of staff compliance with contact precautions, and removal of contact precautions and treatment delay for false-negative test results on the number of secondary colonisations (R) generated per 1000 patients tested by diagnostic approach when 80% of those tested had clinically significant diarrhoea. Lines represent the ends of the range in the number of cases given the best and worst case scenarios tested. CDI, Clostridium difficile infection; GDH, glutamate dehydrogenase; NAAT, nucleic acid amplification test. Clinical Microbiology and Infection 2015 21, 77.e1-77.e9DOI: (10.1016/j.cmi.2014.07.002) Copyright © 2014 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions